A multicenter, single-arm, open-label expanded access program for lenalidomide plus dexamethasone in previously treated subjects with multiple myeloma.
Phase of Trial: Phase III
Latest Information Update: 07 Sep 2016
At a glance
- Drugs Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 02 Aug 2011 New source identified and integrated (European Clinical Trials Database).
- 20 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Oct 2009 Actual patient number (150) added as reported by ClinicalTrials.gov.